BACKGROUND: Despite antiplatelet therapy, some patients remain at high ischemic risk because of drug nonresponsiveness or high residual platelet reactivity). We aimed to target an orphan platelet GPCR ...
Randomized trials of platelet function and genetic testing to guide antiplatelet decisions following PCI have produced notoriously mixed results: now, an updated consensus document aims to fill some ...
WASHINGTON, DC—Additional evidence, this time from a phase IIb trial in healthy people ages 50 to 80, supports that bentracimab (PhaseBio) provides a near-immediate reversal of ticagrelor’s ...
Ado-trastuzumab emtansine (T-DM1) treatment results in grade 3-4 thrombocytopenia in 8%-13% of patients. Prior in vitro studies reported T-DM1 inhibition of megakaryocyte maturation as the cause of ...
Managing drug dosage is critical to the overall success of pharmaceutical intervention, not only in the clinic but also in clinical trials. Inadequate dose management of certain drugs can have fatal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results